DC Funds, LP — Q4 2025 13F-HR

← DC Funds, LP

Q4 2025 · 13F-HR

DC Funds, LPholdings as filed

Filed 2026-02-13 · accession 0001398344-26-002970

$1.5M

Reported value

Positions

2025-12-31

Period end

View analyzed profile →PRO

The Brief · DC Funds, LP · Q4 2025

AI · grounded in 13F

DC Funds, LP reported no changes to its 13F holdings for 2025-12-31 relative to 2025-09-30.

Holdings as filed

CUSIP	Ticker	Issuer	Value	% port.	Shares	Class	Voting
89854M101	TCRX	TSCAN THERAPEUTICS INC	$630,000	43.4%	630,000	Common	SOLE
91864C107	BRNS	BARINTHUS BIOTHERAPEUTICS PL	$449,607	30.9%	642,204	Common	SOLE
95075A107	HOWL	WEREWOLF THERAPEUTICS INC	$373,196	25.7%	589,102	Common	SOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.